^
Association details:
| Biomarker: | BRCA1 mutation + TP53 R248Q |
|---|---|
| Cancer: | Cervical Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report.
Published date:
04/23/2021
Excerpt:
...a TP53 mutation p.Arg248Gln; c.743 G>A validating homologous recombination deficiency (HRD)...deleterious BRCA1 germline mutation (BRCA1 p.His1006Glnfs*17.c.3018_3021delTTCA) that motivated the use of PARPi....the first case of a BRCA1 mutated patient with persistent advanced CC following chemoradiation and chemotherapy showing a complete tumor response after olaparib/bevacizumab adjuvant treatment and 12 months disease-free survival after surgery.
DOI:
https://doi.org/10.1186/s13256-021-02767-9
